Kantarjian et al53 assessed the efficacy and safety of dasatinib, as in contrast with imatinib, for the initial-line procedure of CML-CP. 5 hundred and nineteen people with freshly diagnosed CML-CP ended up randomly assigned to acquire dasatinib in a dose of a hundred mg after each day (259 patients) or https://katherinex863oty6.dm-blog.com/profile